Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.
about
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancerImaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesOverexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors.Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex VivoA phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery.Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast canceIdentification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1.Recent advances in the application of antibodies as therapeutics.How does ionizing irradiation contribute to the induction of anti-tumor immunity?Monoclonal antibodies in lung cancer.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells.Identification of the minimum pharmacophore of lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1D1.Imaging and therapeutic applications of zinc(ii)-dipicolylamine molecular probes for anionic biomembranes.Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer.Targeting Phosphatidylserine with Calcium-Dependent Protein-Drug Conjugates for the Treatment of Cancer.Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment.Newly developed anti-angiogenic therapy in non-small cell lung cancer.
P2860
Q26766332-AE5E0201-8B5D-4330-A7B3-6DA591466C98Q26828959-4CF81C18-6DB8-4629-84EC-980624A7EEF8Q34170756-E3040445-3211-4DF5-BCE2-42EC9FAC1B1EQ34334516-FF64FEB9-43DE-4F2A-8117-C65740C04BA4Q35830423-D7012760-F2A0-47C0-A920-4A4650E4174FQ35928913-2CAC355D-9BB7-47BF-A197-33CD330CDF68Q35949793-B5456B60-9339-4345-BB43-84C35E7EA930Q36895458-E3DE6164-06FC-4DCF-AA22-8A916816E6ACQ37327576-6FBEF5CA-CB8B-4F62-B524-397D5A51500FQ37968255-1AE4B579-F21E-4C56-B1CB-1777326F3ABCQ38030920-4B2EA4E9-77C7-4DD9-A810-C2322543509DQ38067454-CE18214A-B9A5-49BF-B1E8-F8C07FF19A0AQ38525073-8DBDE9E7-3323-4308-8856-F05A74C979E5Q38716057-28AA3907-57AF-479D-A816-4EBE41017CE5Q38754135-A88064CF-7E77-4E54-93FE-A334FEE72158Q38853138-19EF681D-202E-4D01-91FF-E8B6A9937B15Q39139893-977C8FCC-D35B-454B-949F-A5229A3B44BBQ47319293-22EDB64F-97FF-4EE9-B89D-F38DE642119AQ48193673-D21FCA64-90B1-4929-B59F-0A073CE390A9Q52668159-FA55A7E3-7A42-4B25-A1E3-EB6CA188BB71
P2860
Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Development of bavituximab, a ...... es, for lung cancer treatment.
@ast
Development of bavituximab, a ...... es, for lung cancer treatment.
@en
Development of bavituximab, a ...... es, for lung cancer treatment.
@nl
type
label
Development of bavituximab, a ...... es, for lung cancer treatment.
@ast
Development of bavituximab, a ...... es, for lung cancer treatment.
@en
Development of bavituximab, a ...... es, for lung cancer treatment.
@nl
prefLabel
Development of bavituximab, a ...... es, for lung cancer treatment.
@ast
Development of bavituximab, a ...... es, for lung cancer treatment.
@en
Development of bavituximab, a ...... es, for lung cancer treatment.
@nl
P2093
P2860
P356
P1433
P1476
Development of bavituximab, a ...... es, for lung cancer treatment.
@en
P2093
David E Gerber
Paul DeRose
Philip E Thorpe
P2860
P304
P356
10.2217/IMT.11.87
P577
2011-08-01T00:00:00Z